secwatch.observer — SEC 8-K summary
======================================

Issuer:     Nurix Therapeutics, Inc. (NRIX)
CIK:        0001549595
Form:       8-K
Filed at:   2024-10-31T23:59:59+00:00
Accession:  0001193125-24-248678
Event type: other_material
Sentiment:  neutral
Materiality: 0.55
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Nurix Therapeutics files $300M at-the-market stock offering via Piper Sandler
-----------------------------------------------------------------------------

- Amendment No.2 to Equity Distribution Agreement authorizes up to $300M aggregate gross offering price of common stock in ATM offerings.
- Piper Sandler receives up to 3.0% sales commission on gross proceeds; expenses reimbursed up to $50K for this amendment.
- Offering uses existing automatic shelf registration statement (File No. 333-280117) and prospectus supplement dated Oct 31, 2024.
- No specific use of proceeds disclosed in the filing; proceeds will be net of commissions and expenses.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1549595/000119312524248678/0001193125-24-248678-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1549595/000119312524248678/d904494d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-248678

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer